Search the Newsreel

Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen

Replimune announced that the FDA has granted accelerated approval for TUDRIQEVTM (vusolimogene oderparepvec-wtpg) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma who have progressed on anti-PD-1 therapy. This approval is based on objective response rate and duration of response from the …

Melanoma therapy after anti-PD-1 progression gets FDA accelerated approval

Replimune announced that the FDA has granted accelerated approval for TUDRIQEV in combination with nivolumab for adults with unresectable advanced cutaneous melanoma that has progressed on anti-PD-1 therapy. This approval is based on results from the Phase 1/2 IGNYTE trial, showing a 24.2% objective …

Analysts’ Opinions Are Mixed on These Technology Stocks: Eplus (PLUS), OneSpan (OSPN) and IPG Photonics (IPGP)

Analysts have issued mixed opinions on several technology stocks. Eplus (PLUS) received a "Moderate Buy" consensus, with William Blair reiterating a Buy rating. OneSpan (OSPN) was rated "Hold" by BTIG, though the consensus is a "Moderate Buy." IPG Photonics (IPGP) also holds a "Moderate …

ePlus inc. 2027 Q1 - Results - Earnings Call Presentation (NASDAQ:PLUS) 2026-08-06

ePlus inc. (PLUS) published its Q1 2027 earnings call presentation. The company reported an EPS of $1.28, beating estimates by $0.14, and revenue of $649.11M, exceeding expectations by $9.16M with a 1.85% year-over-year increase. The slide deck provides details related to these financial results.

BioLife Solutions (NASDAQ: BLFS) plans cash-stock merger with Repligen

ePlus (PLUS) Stock Cools As Margin Pressure Clouds Backlog Strength

Bragar Eagel & Squire, P.C. is Investigating Replimune Group Inc. on Behalf of Replimune Stockholders and Encourages Investors to Contact the Firm

If you purchased or acquired stock in Replimune and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at investigations@bespc.com or by telephone at (212) 355-4648. Click here to participate in the action. …

CFO of EPLUS INC (PLUS) sells 7,182 shares in Rule 10b5-1 trades

EPLUS INC's Chief Financial Officer, Elaine D. Marion, sold a total of 7,182 shares of common stock on August 3–4, 2026, through open-market transactions. These sales were executed indirectly via a revocable trust under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. …

California State Teachers Retirement System Raises Holdings in Repligen Corporation $RGEN

The California State Teachers Retirement System increased its stake in Repligen Corporation (NASDAQ:RGEN) by 22.1% in the first quarter, now holding 61,860 shares valued at $7.3 million. Repligen exceeded analyst expectations with quarterly revenue of $204.13 million and earnings of $0.54 per share, and …

Moody National Bank Trust Division Makes New Investment in Repligen Corporation $RGEN

Moody National Bank Trust Division has acquired a new stake in Repligen Corporation (NASDAQ:RGEN), purchasing 17,728 shares valued at approximately $2.42 million. This investment comes as institutional investors collectively own 97.64% of the biotechnology company. Repligen recently reported strong quarterly earnings, exceeding analyst expectations …

Biotech Stocks At 52-Week Highs - UFPT +25%, INFU +33%, SOPH +20% On Q2 Reports, REPL, PBLS

(RTTNews) - The following biotech stocks reached a 52-week high on August 4, 2026, driven by key catalysts like positive quarterly results or certain regulatory milestones. UFP Technologies Inc. (UFPT) UFP Technologies is a contract development and manufacturing organization specializing in solutions for medical …

Earnings Flash (PLUS) ePlus inc. Reports Q1 Revenue $649.1M, vs. FactSet Est of $640.0M

ePlus inc. reported its Q1 revenue reached $649.1 million, surpassing FactSet's estimate of $640.0 million. The company also posted Q1 adjusted EPS of $1.28 per share, exceeding the FactSet estimate of $1.19. This financial update indicates a stronger-than-expected performance for the quarter.

The Bull Case For ePlus (PLUS) Could Change Following Q1 Earnings, Payout Moves, And Share Expansion Plans - Learn Why

ePlus (NASDAQ:PLUS) Surprises With Q2 CY2026 Sales

Earnings call transcript: ePlus tops Q1 2026 estimates as AI demand lifts shares

ePlus exceeded Q1 2027 earnings and revenue expectations, driven by strong demand in AI infrastructure and security, despite challenging year-over-year comparisons. The company reported adjusted EPS of $1.28 and revenue of $649.1 million, leading to a 5.7% stock increase after hours. Management affirmed fiscal …

REPL SHAREHOLDER ALERT: Replimune Group Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

Kirby McInerney LLP is investigating Replimune Group Inc. (NASDAQ: REPL) following a significant drop in its stock price. The decline occurred after the FDA deemed Replimune's mid-stage study for its skin cancer drug "non interpretable," raising concerns about potential federal securities law violations. Investors …

ePlus Q1 Fiscal 2027 Net Sales Rise To $649.1 Million

ePlus (PLUS) announced a 1.0% increase in net sales to $649.1 million for the first quarter of fiscal 2027, although net earnings from continuing operations decreased by 5.4%. The company reiterated its fiscal 2027 guidance for mid-single-digit growth in net sales, gross profit, and …

EPLUS INC 2026: Revenue $649.11M, EPS $1.16— 10-Q Summary

EPLUS INC reported its 2026 quarterly results with revenue of $649.11M, a modest increase from the prior year, while net income and diluted earnings per share saw a decline. The company's revenue growth was driven by product and managed services gains, despite a decrease …

EPLUS (PLUS) trust details Rule 144 sales and stock awards

An affiliate of an EPLUS shareholder filed a Rule 144 notice to sell common stock through Rockefeller Capital Management. The filing details prior stock awards of 5,000 shares each on several dates in 2024 and 2025. It also reports recent sales by the Elaine …

ePlus (PLUS) trust plans NASDAQ sale of 200 shares under Form 144

The Darren S Raiguel Trust, associated with ePlus (PLUS), has filed a Form 144 indicating its intent to sell 200 shares of common stock through Rockefeller Capital Management on or about August 4, 2026. The proposed sale has an indicated value of $19,582.63 and …

Earnings Flash (PLUS) ePlus inc. Posts Q1 Adjusted EPS $1.28 per Share, vs. FactSet Est of $1.19

ePlus inc. (PLUS) announced its Q1 adjusted earnings per share (EPS) of $1.28, surpassing the FactSet estimate of $1.19. The company's Q1 revenue also rose, reaching $649.1 million against an estimated $640.0 million. The report indicates a positive financial performance for the IT solutions …

ePlus in the spotlight as earnings loom after AI-fueled year

ePlus Inc. is preparing to report its first-quarter fiscal 2027 earnings, with investors focused on whether the AI infrastructure boom that fueled its previous year's success can continue. Analysts anticipate earnings of $1.19 per share on revenue of $631.35 million. Key areas of interest …

Replimune Group : REPL

This article provides an overview of Replimune Group Inc. (REPL), a biotechnology firm specializing in oncolytic immunotherapies for cancer treatment. It

Leerink Partners Upgrades Replimune Group to Outperform From Market Perform, Adjusts Price Target to $17 From $11

Leerink Partners has upgraded Replimune Group to "Outperform" from "Market Perform" and raised its price target to $17 from $11. This upgrade follows a series of positive developments for Replimune, including favorable outcomes from an FDA Advisory Committee meeting for its lead product candidate, …

Class Action Alert: Levi & Korsinsky Reminds Replimune Group, Inc. (REPL) Investors of September 22, 2025 Deadline

Levi & Korsinsky reminds investors of Replimune Group, Inc. (REPL) about a class action lawsuit with a September 22, 2025 deadline. The lawsuit alleges that Replimune Group, Inc. made false and misleading statements about the IGNYTE trial, which the FDA deemed inadequate. Investors who …

Repligen Corporation (BLFS) sets cash and stock terms for BioLife Solutions buyout

Repligen Corporation has announced an agreement to acquire BioLife Solutions for a combination of cash and stock. BioLife shareholders will receive $11.25 in cash plus 0.1442 shares of Repligen common stock for each BioLife share. The transaction, described as a strategic combination in the …

EPL Limited Q1 Results: Conference Call Scheduled for Aug 11

BioLife Solutions (NASDAQ: BLFS) shares Repligen merger video with staff

BioLife Solutions (NASDAQ: BLFS) has informed its employees about its pending merger with Repligen Corporation, distributing an internal email with a video from Repligen's CEO. The video introduces Repligen and discusses the anticipated benefits of the combination, particularly growth opportunities in the cell therapy …

ePlus (NASDAQ: PLUS) trust plans 1,668-share sale after prior 2,818-share trade

A trust associated with ePlus (NASDAQ: PLUS) is planning to sell 1,668 common shares valued at $158,659.50 on or after August 3, 2026. This follows a previous sale of 2,818 shares by the same trust on July 29, 2026, which generated $268,336.48. The shares …

How Repligen Corporation (RGEN) Affects Rotational Strategy Timing

This article analyzes Repligen Corporation (RGEN) using AI models to offer trading strategies. It highlights a strong near-term sentiment with a neutral mid- and long-term outlook, identifying an exceptional risk-reward setup. The analysis provides specific entry, target, and stop-loss levels for position, momentum, and …

Repligen Number of Employees 2026 | Employee Count & Headcount Data

Repligen Corp. (NASDAQ: RGEN) had approximately 1,994 employees worldwide as of March 2026, representing a 1.7% growth from 2023. The company is actively hiring, though job postings declined by 16.1% in 2026. The majority of its workforce is located in the United States, and …

Repligen: Acquisition To Add Cell Therapy Capabilities (NASDAQ:RGEN)

What To Expect From ePlus’s (PLUS) Q2 Earnings

Why Repligen (RGEN) Is Up 6.9% After Mixed Q2 2026 Results With Higher Revenue And Lower EPS

Repligen (RGEN) stock increased by 6.9% despite mixed Q2 2026 results which showed higher revenue but lower EPS. The company reported revenue of US$204.13 million, up from US$182.37 million year-over-year, but net income and diluted EPS declined. Analysts have revised earnings estimates higher, maintaining …

Why Replimune Group (REPL) Is Up 15.5% After Key FDA Panel Backing For RP1 Data - And What's Next

Replimune Group's stock (REPL) rose 15.5% after an FDA advisory committee voted 10–3 that the efficacy data from its IGNYTE trial for RP1 in advanced melanoma are evaluable and clinically meaningful, ahead of an August 2, 2026 action date. The article highlights the importance …

Liquidity Mapping Around (PLUS) Price Events

This article from Stock Traders Daily provides an AI-driven analysis of Eplus Inc. (NASDAQ: PLUS), highlighting strong sentiment across all time horizons. It outlines institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis to guide potential trades. The …